Type 2 Diabetes Mellitus
Conditions
Keywords
diabetes
Brief summary
The primary purpose of this trial is to assess the safety of ISIS 325568 when given at increasing single doses and to assess the safety of the same doses when given multiple times.
Detailed description
To evaluate the safety of a single subcutaneous injection of ISIS 325568 administered at four increasing dose levels (50, 100, 200, 400 mg/week) and to evaluate the safety and tolerability of multiple doses of ISIS 325568 (three intravenous doses during Study Week 1, followed by once weekly subcutaneous administration for 5 weeks) at each of the four dose levels
Interventions
DRUGISIS 325568
4 arms of single dose s.c. injections: A 50 mg B 100 mg C 200 mg D 400 mg 4 arms of multi-dose: 3 i.v. infusions over 1 week followed by 5 weekly s.c. injections AA 50 mg BB 100 mg CC 200 mg DD 400 mg or EE 50 mg Placebo: 0.9% Sodium Chloride
Sponsors
Ionis Pharmaceuticals, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
1. Age 18 to 65 years 2. Males or females. Females must be non-pregnant and non-lactating, and either surgically sterile (hysterectomy, oophorectomy, or tubal ligation) or post-menopausal. Males must be surgically sterile, abstinent or if engaged in sexual relations of child-bearing potential, subject or partner must be using an acceptable contraceptive method during the trial and for 9 weeks after the last dose of study drug. 3. Give written informed consent to participate in study and availability for all study requirements 4. Fasting plasma glucose ≤ the upper limit of the laboratory's reference range (ULN) 5. HbA1C ≤ ULN 6. BMI \< 30 kg/m2
Exclusion criteria
1. Clinically significant abnormalities in medical history or physical examination 2. Abnormalities on laboratory examination (ALT \> ULN, AST \> ULN, bilirubin \> ULN, creatinine \> ULN, urine protein positive by urine dipstick, platelets \< lower limit of normal and any other clinically significant laboratory findings) 3. History of clinically significant abnormalities in coagulation parameters 4. Positive test result for HIV, hepatitis B virus, and/or hepatitis C virus 5. Active infection requiring antiviral or antimicrobial therapy 6. Subjects on chronic or acute prescription medication may be permitted after discussion with the Isis Medical Monitor. 7. Malignancy (with the exception of basal or squamous cell carcinoma of the skin if adequately treated and no recurrence for \> 1 year) 8. Any other concurrent condition which, in the opinion of the Investigator, would preclude participation in this study or interfere with compliance 9. History of alcohol or drug abuse 10. Undergoing or have undergone treatment with another investigational drug, biologic agent or device within 90 days prior to Screening. 11. Blood donation within three months of screening
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety and tolerability | 30 days for single dose, 16 weeks for multi-dose |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacokinetic profile all doses and Pharmacodynamics for multi-dose groups. | 4 days for single dose, 16 weeks for multi-dose |
Countries
Netherlands
Outcome results
None listed